Serving leading biopharmaceutical companies globally:

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

JETREA Drug Profile

See Plans and Pricing

« Back to Dashboard

Summary for Tradename: JETREA

Patents:	8
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for JETREA

Recent Clinical Trials for JETREA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Universitaire Ziekenhuizen Leuven	Phase 1
Katholieke Universiteit Leuven	Phase 1
Alcon Research	Phase 4

See all JETREA clinical trials

Pharmacology for JETREA

Ingredient-type	Peptide Hydrolases

Company Disclosures: US Patents for JETREA

These patents were extracted from company disclosures

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Thrombogenics, Inc	JETREA	ocriplasmin	INJECTABLE; INTRAVITREAL	125422	001	2012-10-17	Start Trial	Thromb-X nv (Leuven, BE)	2020-12-21	RX		company
Thrombogenics, Inc	JETREA	ocriplasmin	INJECTABLE; INTRAVITREAL	125422	001	2012-10-17	Start Trial	ThromboGenics NV (Leuven, BE)	2022-12-06	RX		company
Thrombogenics, Inc	JETREA	ocriplasmin	INJECTABLE; INTRAVITREAL	125422	001	2012-10-17	Start Trial	ThromboGenics NV (Heverlee, BE)	2022-12-06	RX		company
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

Patent Text Search: US Patents for JETREA

These patents were identified by searching patent claims

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Thrombogenics, Inc	JETREA	ocriplasmin	INJECTABLE; INTRAVITREAL	125422	001	2012-10-17	Start Trial	OcuJect, LLC (Newport Beach, CA)	2032-04-02	RX		search
Thrombogenics, Inc	JETREA	ocriplasmin	INJECTABLE; INTRAVITREAL	125422	001	2012-10-17	Start Trial	Corning Incorporated (Corning, NY)	2031-10-25	RX		search
Thrombogenics, Inc	JETREA	ocriplasmin	INJECTABLE; INTRAVITREAL	125422	001	2012-10-17	Start Trial	OcuJect, LLC (Newport Beach, CA)	2032-04-02	RX		search
Thrombogenics, Inc	JETREA	ocriplasmin	INJECTABLE; INTRAVITREAL	125422	001	2012-10-17	Start Trial	OcuJect, LLC (Newport Beach, CA)	2032-04-02	RX		search
Thrombogenics, Inc	JETREA	ocriplasmin	INJECTABLE; INTRAVITREAL	125422	001	2012-10-17	Start Trial	Wayne State University (Detroit, MI)	2033-03-14	RX		search
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

International Patents for JETREA

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Spain	2296705	Start Trial
Israel	213838	Start Trial
United Kingdom	0116690	Start Trial
World Intellectual Property Organization (WIPO)	2014160281	Start Trial
Japan	2016519063	Start Trial
Japan	2006518708	Start Trial
South Africa	200505193	Start Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for JETREA

Subscribe to access the full database, or Start Trial
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
13C0052	France	Start Trial	PRODUCT NAME: MICROPLASMINE; REGISTRATION NO/DATE: EU/1/13/819/001 20130313
122013000076	Germany	Start Trial	PRODUCT NAME: MIKROPLASMIN; REGISTRATION NO/DATE: EU/1/13/819/001 20130313
C300611	Netherlands	Start Trial	PRODUCT NAME: MICROPLASMINE; REGISTRATION NO/DATE: EU/1/13/819/001 20130313
2013C/055	Belgium	Start Trial	DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGEMENT DE NOM DU PROPRIETAIRE
47/2013	Austria	Start Trial	PRODUCT NAME: OCRIPLASMIN; REGISTRATION NO/DATE: EU/1/13/819/001 (MITTEILUNG) 20130315
PA2013020,C1581254	Lithuania	Start Trial	PRODUCT NAME: OCRIPLASMINUM (MICROPLASMINUM); REGISTRATION NO/DATE: EU/1/13/819/001 20130313
C20130023 00082	Estonia	Start Trial	PRODUCT NAME: OKRIPLASMIIN;REG NO/DATE: K(2013)1648 (LOPLIK) 13.03.2013
>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt

McKesson

McKinsey

Moodys

Express Scripts

Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.